Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in newly diagnosed advanced NSCLC
NCT00391586Phase 2Terminated
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Jul 2006
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by New Mexico Cancer Research Alliance. Primary endpoints: Progression-free Survival at 5 years and Toxicity Profile. Started Jul 2006; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00391586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391586.